Meeting
2023 ASCO Annual Meeting
Enzalutamide vs abiraterone in patients with prostate cancer with and without type 2 diabetes mellitus.
Authors
Amy L Shaver
Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA
Amy L Shaver , Nikita Nikita , Krupa Gandhi , Swapnil Sharma , Scott W. Keith , Christopher C. Yang , Grace L. Lu-Yao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Castrate-Resistant
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5066)
DOI
10.1200/JCO.2023.41.16_suppl.5066
Abstract #
5066
Poster Bd #
160
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Survival in Black and non-Black patients with metastatic prostate cancer.
First Author: Nina Cheranda
Poster
2021 ASCO Annual Meeting
Survival of veterans treated with enzalutamide and abiraterone in advanced prostate cancer.
First Author: Martin W. Schoen
Poster
2022 ASCO Quality Care Symposium
Adverse events associated with androgen receptor signaling inhibitors in the treatment of prostate cancer: A systematic review and network meta-analysis.
First Author: Brent Cao
Poster
2022 ASCO Genitourinary Cancers Symposium
Treatment outcomes of patients with metastatic prostate cancer and co-morbid diabetes mellitus.
First Author: Srinivas Govindan